Stocks Health care TENX
NASDAQ · Health careTenax Therapeutics, Inc. (TENX)
It posted a net loss of $64.9M. At June 30, 2026 it held $118M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 31, 2026.
Key facts about Tenax Therapeutics, Inc.
- Net worth
- Tenax Therapeutics, Inc. has a market value (market cap) of $63.2M at the latest share price, and shareholders' equity of $113.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $0, with a net loss of $52.6M.
- Cash flow
- In fiscal 2025 operations used $35.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on July 31, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Tenax Therapeutics, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Tenax Therapeutics, Inc. does
Tenax Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TENX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$52.6M | -$1.34 | n/a |
| 2024 | $0 | -$17.6M | -$1.15 | n/a |
| 2023 | n/a | -$7.7M | -$31.04 | n/a |
| 2022 | n/a | $11M | n/a | -$11.4M |
| 2021 | n/a | -$32.5M | -$1.58 | -$10.9M |
| 2020 | n/a | -$9.9M | -$0.95 | -$9.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Tenax Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 11, 2026Passive stake changed SCHEDULE 13G/A
- September 9, 2026
- September 8, 2026Passive stake (5% or more) SCHEDULE 13G
- September 8, 2026Passive stake changed SCHEDULE 13G/A
- August 27, 2026Passive stake (5% or more) SCHEDULE 13G
- August 27, 2026Passive stake (5% or more) SCHEDULE 13G
- August 18, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Tenax Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $4.9M worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 16, 2026 | Doogan DeclanDirector | Bought | 53,000 | $101.8K |
| September 15, 2026 | Giordano Christopher ThomasCEO, Director | Bought | 4,850 | $8.8K |
| September 11, 2026 | Staab Thomas R IIChief Financial Officer | Bought | 5,675 | $11K |
| September 11, 2026 | Giordano Christopher ThomasCEO, Director | Bought | 6,000 | $11.3K |
| September 3, 2026 | ADAR1 Capital Management, LLC10% owner | Boughtindirect | 900,000 | $1.6M |
| September 2, 2026 | ADAR1 Capital Management, LLC10% owner | Boughtindirect | 187,704 | $337.6K |
| September 1, 2026 | ADAR1 Capital Management, LLC10% owner | Boughtindirect | 179,058 | $321.6K |
| August 31, 2026 | ADAR1 Capital Management, LLC10% owner | Boughtindirect | 403,571 | $722.6K |
Who owns TENX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| ADAR1 Capital Management, LLC13G, passive with 1 related filers | 14% | September 8, 2026 |
| Bvf Partners L P13G, passive with 9 related filers | 9.99% | August 14, 2026 |
| Janus Henderson Group PLC13G, passive | 9.99% | December 8, 2025 |
| RTW Investments, LP13G, passive with 1 related filers | 9.9% | August 14, 2026 |
| Vestal Point Capital, LP13G, passive with 1 related filers | 9.9% | November 14, 2025 |
| Vivo Opportunity Fund Holdings, L.P.13G, passive with 1 related filers | 9% | August 14, 2026 |
| Integrated Core Strategies (US) LLC13G, passive with 3 related filers | 6.9% | November 5, 2025 |
| Adage Capital Management, L.P.13G, passive with 2 related filers | 6.81% | August 12, 2026 |
| Millennium Management LLC13G, passive with 2 related filers | 5.8% | August 18, 2026 |
| Sphera Funds Management Ltd.13G, passive with 2 related filers | 5.33% | August 27, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 111 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 3,942,373 | +3,619,773 |
| Vivo Capital, LLC | 2,500,000 | +2,291,667 |
| BlackRock, Inc. | 1,727,988 | +1,711,011 |
| Perceptive Advisors LLC | 1,700,000 | +252,218 |
| Vanguard Capital Management LLC | 1,147,121 | +883,700 |
| Millennium Management LLC | 876,230 | +342,341 |
| Ikarian Capital, LLC | 787,600 | -230,000 |
| Candriam S.C.A. | 749,588 | new |
| Citadel Advisors LLC | 728,561 | +576,045 |
| Rtw Investments, LP | 696,570 | +326,324 |
| Stonepine Capital Management, LLC | 660,000 | -315,200 |
| Geode Capital Management, LLC | 639,537 | +570,377 |
| Marshall Wace, Llp | 585,578 | +233,006 |
| Braidwell LP | 584,412 | new |
| Point72 Asset Management, L.P. | 556,761 | +22,796 |
| Velan Capital Investment Management LP | 549,985 | -33,348 |
| Adage Capital Partners GP, L.L.C. | 540,126 | 0 |
| Woodline Partners LP | 531,254 | +207,343 |
| State Street Corp | 510,814 | +481,824 |
| Sofinnova Investments, Inc. | 500,039 | +395,639 |
Insiders
7 insiders reported holding 6,638,526 shares in total, about $11.2M at the last price.
| Holder | Shares |
|---|---|
| ADAR1 Capital Management, LLC10% owner | 6,524,1516,524,151 held indirectly |
| Doogan DeclanDirector | 55,274 |
| Giordano Christopher ThomasCEO, Director | 22,174 |
| Staab Thomas R IIChief Financial Officer | 15,675 |
| Rich StuartChief Medical Officer, Director | 10,2665,000 held indirectly |
| Mcgauley ThomasInterim CFO | 7,0005,000 held indirectly |
| Almenoff June SherieDirector | 3,9861,993 held indirectly |
Questions about TENX
What does Tenax Therapeutics, Inc. do?
Tenax Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as TENX. Its shares trade on NASDAQ under the ticker TENX.
What is Tenax Therapeutics, Inc.'s net worth?
Tenax Therapeutics, Inc. has a market value (market cap) of $63.2M at the latest share price, and shareholders' equity of $113.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Tenax Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $64.9M.
When did Tenax Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 31, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 17, 2026.
When is Tenax Therapeutics, Inc.'s next earnings report?
Tenax Therapeutics, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare TENX with
Follow TENX
Get an email when Tenax Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Tenax Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.